Volume 26, Number 9—September 2020
Research
Detection of H1 Swine Influenza A Virus Antibodies in Human Serum Samples by Age Group1
Elien Vandoorn, Isabel Leroux-Roels, Geert Leroux-Roels, Anna Parys, Amy Vincent, and Kristien Van Reeth
Table 6
Geometric mean of hemagglutination inhibition antibody reactivity against different H1 influenza A viruses of humans and swine in different age groups of the population, 2017–2018, Belgium*
| Birth year range
(age, y‡) |
No. |
Eurasian avian |
Human seasonal |
Classical swine |
|||||||||||
| swG10 |
swHK11 |
TW86† |
swG12 |
NC99† |
swAL16 |
swIL10 |
swOK13 |
BR07† |
swOH07 |
CA09 |
|||||
| Eur. 1C.2.1 |
Asia 1C.2.3 |
1B.1-like |
Eur. 1B.1.2.1 |
1B.2-like |
N. Am. 1B.2.2.1 |
N. Am. 1B.2.2.2 |
N. Am. 1B.2.2.2 |
1B.2-like |
N. Am. 1A.3.3.3 |
World 1A.3.3.2 |
|||||
| 1920–26 (91–97) | 25 | 24 (16–38) | 38 (24–60) | 21 (15–31) | 26 (18–39) | 25 (18–35) | 24 (17–35) | 14 (11–17) | 12 (10–16) | 19 (14–28) | 236 (147–379) | 125 (70–222) | |||
| 1927–36 (81–90) | 60 | 15 (12–19 | 20 (16–26) | 38 (29–51) | 49 (39–61) | 24 (20–28) | 20 (17–24) | 15 (13–18) | 12 (11–13) | 18 (15–20) | 116 (87–155) | 98 (73–132) | |||
| 1937–46 (71–80) | 58 | 12 (10–13) | 15 (12–18) | 26 (19–36) | 30 (22–40) | 16 (13–20) | 14 (12–17) | 12 (11–14) | 12 (10–13) | 12 (11–13) | 23 (17–31) | 28 (20–38) | |||
| 1947–56 (61–70) | 54 | 10 (10–11) | 12 (11–14) | 17 (13–23) | 19 (15–25) | 14 (12–17) | 16 (13–20) | 12 (11–14) | 10 (10–11) | 11 (10–13) | 15 (12–19) | 18 (14–23) | |||
| 1957–66 (51–60) | 55 | 11 (10–13) | 14 (12–17) | 31 (22–42) | 55 (42–72) | 17 (13–21) | 16 (14–20) | 11 (10–12) | 11 (10–12) | 13 (11–16) | 25 (20–32) | 32 (24–44) | |||
| 1967–76 (41–50) | 57 | 12 (11–14) | 18 (14–23) | 34 (26–44) | 76 (60–97) | 16 (13–20) | 14 (12–16) | 12 (10–13) | 12 (11–14) | 14 (12–17) | 23 (18–29) | 25 (19–33) | |||
| 1977–86 (31–40) | 58 | 14 (12–17) | 25 (19–32) | 97 (68–138) | 87 (69–110) | 42 (31–57) | 22 (17–28) | 17 (14–21) | 18 (15–22) | 29 (23–38) | 27 (22–34) | 39 (28–54) | |||
| 1987–96 (21–30) | 65 | 13 (11–16) | 19 (16–23) | 45 (32–65) | 37 (28–50) | 42 (32–54) | 35 (28–44) | 15 (12–17) | 13 (12–15) | 40 (31–52) | 37 (28–48) | 54 (39–74) | |||
| 1997–2006 (11–20) | 59 | 14 (12–17) | 21 (17–27) | 13 (11–15) | 13 (11–15) | 22 (18–28) | 19 (15–23) | 14 (12–16) | 11 (10–12) | 18 (15–23) | 48 (35–66) | 73 (49–109) | |||
| 2007–17
(0–10) |
58 |
13
(11–16) |
18
(13–24) |
11
(10–12) |
11
(10–12) |
10
(10–11) |
10
(10–10) |
11
(10–12) |
10
(10–10) |
10
(10–10) |
24
(18–33) |
35
(24–53) |
|||
| All (0–97) |
549 |
13
(13–14) |
18
(17–20) |
28
(25–31) |
33
(30–36) |
21
(19–23) |
18
(17–19) |
13
(13–14) |
12
(12–12) |
17
(16–18) |
35
(31–38) |
42
(37–47) |
|||
| *Values expressed represent geometric mean hemagglutination inhibition titers (95% CI). Eur., Europe; N. Am., North America.
†Human IAV that no longer circulates; TW86 is the presumed human precursor for human-like H1 swine IAVs in Europe; NC99 is the presumed human precursor for human-like H1 swine IAVs in North America; BR07 is a human seasonal IAV that circulated right before the influenza A(H1N1)pdm09 virus; the influenza A(H1N1)pdm09 virus, represented by CA09, is circulating in both humans and swine worldwide.
‡Age at the end of 2017. |
|||||||||||||||
1Preliminary results from this study were presented at the Fourth International Symposium on Neglected Influenza Viruses, April 18–20, 2018, Brighton, United Kingdom; at the BELVIR conference, December 20, 2018, Brussels, Belgium; and at the 1918 Pandemic Conference, February 7–8, 2019, Ypres, Belgium.
Page created: July 06, 2020
Page updated: August 18, 2020
Page reviewed: August 18, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.